The menu-setting problem and subsidized prices: Drug formulary illustration

Journal of Health Economics

Volumn 18, Issue 5, 1999, Pages 523-550

  Olmstead, Todd ^a   Zeckhauser, Richard ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Constrained maximization; Cost effective; Drug formulary; Menu setting; Subsidy

Indexed keywords

COST BENEFIT ANALYSIS; DECISION MAKING; DRUG FORMULARY; HEALTH CARE COST; MODEL; PRESCRIPTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; STANDARDIZATION;

EID: 0032818813     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-6296(99)00010-7     Document Type: Article

References (49)

1. American Society of Hospital Pharmacists ASHP statement on the formulary system. American Journal of Hospital Pharmacy. 43:1986;2839-2841.
2. American Society of Hospital Pharmacists The formulary system: brief history and 1960's perspective. American Journal of Hospital Pharmacy. 43:1986;2838-2839.
3. American Society of Hospital Pharmacists, 1991. Practice standards of ASHP 1991-1992, American Society of Hospital Pharmacists, Bethesda, MD.
4. Bakst A. Pharmacoeconomics and the formulary decision-making process. Hospital Formulary. 30:1995;42-49.
5. Bakst, A., 1998. Personal interview, August: Associate Director, Outcomes Research and Pharmacoeconomics, Smith-Kline Beecham.
6. Barriere S. Formulary evaluation of second-generation cephamycin derivatives using decision analysis. American Journal of Hospital Pharmacy. 48:1991;2146-2150.
7. Basskin, L., 1998. Personal interview: PharmD, Director of postgraduate education and assistant professor of pharmacoeconomics and outcomes research, Butler University, Indianapolis.
8. Baumgardner J.R. The interaction between forms of insurance contract and types of technical change in medical care. RAND Journal of Economics. 22:1991;36-53.
9. Birch S., Donaldson C. Applications of cost-benefit analysis to health care: departures from welfare economic theory. Journal of Health Economics. 6:1987;211-225.
10. 2-receptor antagonists for the formulary. American Journal of Hospital Pharmacy. 47:1990;2002-2006.
11. Cano S., Fujita N. Formulary evaluation of third-generation cephalosporins using decision analysis. American Journal of Hospital Pharmacy. 45:1988;566-569.
12. Caul, A., 1998. Personal interview, August: President, Medical Outcomes Management, Foxboro, MA, formerly Chief of Pharmacy at Brigham and Women's Hospital.
13. Chinburapa V., Larson L. Predicting prescribing intention and assessing drug attribute importance using conjoint analysis. Journal of Pharmaceutical Marketing and Management. 3:1989;3-18.
14. Detsky A. Using cost-effectiveness analysis for formulary decision making: from theory into practice. PharmacoEconomics. 6:1994;281-288.
15. Dobson G., Kalish S. Heuristics for pricing and positioning a product line using conjoint and cost data. Management Science. 39:1993;160-173.
16. Einarson T., Arikian S., Sweeney S., Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clinical Therapeutics. 17:1995;136-153.
17. Freundlich, N., 1995. Formularies: friend or foe?, The Harvard Health Letter, President and Fellows of Harvard College, Cambridge, MA.
18. Gafni A., Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Canadian Medical Association Journal. 148:1993;913-917.
19. Garrelts, J., 1997. Personal interview: Interim Director of Pharmacies, Via Christi-St. Francis Medical Center, Wichita, KS.
20. Glomski, S., 1998. Personal interview, August: Pharmacist, Via Christi-St. Francis Medical Center, Wichita, KS.
21. Green P., Krieger A. Models and heuristics for product-line selection. Marketing Science. 4:1985;1-19.
22. GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New England Journal of Medicine. 329:1993;673-682.
23. Harsanyi J. Cardinal welfare, individualistic ethics and interpersonal comparisons of utility. Journal of Political Economy. 63:1955;309-321.
24. Harvey R., Comer C., Sanders B., Westley R., Marsh W., Shapiro H., Wiener M. Model of outcomes assessment of antihistamine use for seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 97:1996;1233-1241.
25. Horn S., Sharkey P., Tracy D., Horn C., James B., Goodwin F. Intended and unintended consequences of HMO cost constraint strategies: results from the Managed Care Outcomes Project. American Journal of Managed Care. 2:1996;253-264.
26. Hornberger J., Habraken H., Bloch D. Minimum data needed on patient preferences for accurate, efficient medical decision making. Medical Care. 33:1995;297-310.
27. Johannesson M., Pliskin J., Weinstein M. Are healthy-years equivalents an improvement over quality-adjusted life years? Medical Decision Making. 13:1993;281-286.
28. Joint Commission on Accreditation of Hospitals, 1965. Accreditation manual for hospitals, JCAH, Chicago.
29. Kresel J., Hutchings H., MacKay D., Weinstein M., Read J., Taylor-Halvorsen K., Ashley H. Application of decision analysis to drug selection for formulary addition. Hospital Formulary. 22:1987;658-676.
30. Lee J., Glick H., Kinosian B., Schulman K. An interactive computer system for formulary management using cost-effectiveness analysis. M.D. Computing: Computers in Medical Practice. 12:1995;59-65.
31. Levy, R., 1993. Ethnic and racial differences in response to medicines: preserving individualized therapy in managed pharmaceutical programs. National Pharmaceutical Council, Reston, VA.
32. Maas A., Stalpers L. Assessing utilities by means of conjoint measurement: an application in medical decision analysis. Medical Decision Making. 12:1992;288-297.
33. McLaughlin, T., 1998. Personal interview, August: Assistant Professor, Harvard Medical School.
34. Mehrez A., Gafni A. Quality-adjusted life-years, utility theory and healthy-years equivalents. Medical Decision Making. 9:1989;142-149.
35. Nash, D., 1998. Personal interview, August: MD/MBA, Associate Dean, Jefferson Medical College, Philadelphia, PA.
36. Nash D., Catalano M., Wordell C. The formulary decision-making process in a US academic medical centre. PharmacoEconomics. 3:1993;22-35.
37. Newhouse, J.P., 1998. Private communication, July 13.
38. Olmstead, T., Zeckhauser, R., 1996. Menu-setting problems. Unpublished manuscript, John F. Kennedy School of Government, Harvard University. Cambridge, MA.
39. Pratt, J., Zeckhauser, R., 1991. Principals and Agents: The Structure of Business. Harvard Business School Press, Boston, MA.
40. Rascati L. Survey of formulary system policies and procedures. American Journal of Hospital Pharmacy. 49:1992;100-103.
41. Rucker T., Schiff G. Drug formularies: myths-in-formation. Medical Care. 28:1990;928-942.
42. Schumacher G. Multiattribute evaluation in formulary decision making as applied to calcium-channel blockers. American Journal of Hospital Pharmacy. 48:1991;301-308.
43. Seaver, D., 1995. Personal interview: RPH, Esq., Consultant, Pharmaceutical Strategies.
44. Senthilkumaran K., Shatz S., Kalies R. Computer-based support system for formulary decision. American Journal of Hospital Pharmacy. 44:1987;1362-1366.
45. Shoop J. Jury holds HMO liable for refusing coverage. Trial. 30:1994;90-91.
46. Sorrenti, R., 1998. Personal interview, August: MD, Medical Director, Group Insurance Commission Indemnity Plan, Vice President, Unicare Life and Health Insurance, Massachusetts.
47. U.S. Congress, House Committee on Government Operations, Human Resources and Intergovernmental Relations Subcommittee, 1995. State medicaid drug formularies: cost saving measure or second-class medicine? U.S. Government Printing Office, Washington, DC.
48. Willke R. What's all this about pharmacoeconomics? Business Economics. 30:1995;26-31.
49. Zeckhauser R., Shepard D. Where now for saving lives? Law and Contemporary Problems. 40:1976;5-45.